{"altmetric_id":2198613,"counts":{"readers":{"mendeley":129,"citeulike":0,"connotea":0},"policy":{"unique_users_count":1,"unique_users":["nice"],"posts_count":1},"total":{"posts_count":10},"twitter":{"unique_users_count":8,"unique_users":["aftimosp","PenrynPam","TripCancer","JRBtrip","tripdatabase","Senology","BibliotecaHUVH","CRWLibrary"],"posts_count":9}},"selected_quotes":["Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH)","Benefit from trastuzumab-containing neoadjuvant therapy followed by adjuvant #trastuzumab in advanced breast #cancer","#hvhebron participa Neoadjuvant and adjuvant trastuzumab in patients with HER2positive locally advanced breast cancer","Neoadjuvant adjuvant trastuzumab in patients with HER2-positive locally advanced #breastcancer (NOAH)"],"citation":{"altmetric_jid":"4f6fa4f73cf058f610002fd1","authors":["Luca Gianni","Wolfgang Eiermann","Vladimir Semiglazov","Ana Lluch","Sergei Tjulandin","Milvia Zambetti","Angela Moliterni","Federico Vazquez","Mikhail J Byakhov","Mikhail Lichinitser","Miguel Angel Climent","Eva Ciruelos","Belen Ojeda","Mauro Mansutti","Alla Bozhok","Domenico Magazz\u00f9","Dominik Heinzmann","Jutta Steinseifer","Pinuccia Valagussa","Jose Baselga"],"doi":"10.1016\/s1470-2045(14)70080-4","first_seen_on":"2014-03-20T00:43:43+00:00","issns":["1470-2045","14702045"],"journal":"Lancet Oncology","last_mentioned_on":1463702400,"links":["http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(14)70080-4\/abstract?rss=yes&utm_source=twitterfeed&utm_medium=twitter","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1470204514700804","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(14)70080-4\/abstract","http:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045%2814%2970080-4\/abstract","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24657003?dopt=Abstract","http:\/\/dx.doi.org\/10.1016\/S1470-2045(14)70080-4"],"pdf_url":"http:\/\/download.thelancet.com\/pdfs\/journals\/lanonc\/PIIS1470204514700804.pdf","pmid":"24657003","pubdate":"2014-05-01T00:00:00+00:00","publisher":"Elsevier","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neoplasms"],"title":"Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/neoadjuvant-adjuvant-trastuzumab-patients-her2positive-locally-advanced-breast-cancer-noah-followup"},"altmetric_score":{"score":6,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":6},"context_for_score":{"all":{"total_number_of_other_articles":7772166,"mean":6.6362066801147,"rank":1226364,"this_scored_higher_than_pct":83,"this_scored_higher_than":6487557,"rank_type":"exact","sample_size":7772166,"percentile":83},"similar_age_3m":{"total_number_of_other_articles":174194,"mean":7.4630040472353,"rank":30718,"this_scored_higher_than_pct":82,"this_scored_higher_than":143257,"rank_type":"exact","sample_size":174194,"percentile":82},"this_journal":{"total_number_of_other_articles":3408,"mean":16.949712943939,"rank":1262,"this_scored_higher_than_pct":62,"this_scored_higher_than":2128,"rank_type":"exact","sample_size":3408,"percentile":62},"similar_age_this_journal_3m":{"total_number_of_other_articles":64,"mean":21.849015873016,"rank":36,"this_scored_higher_than_pct":43,"this_scored_higher_than":28,"rank_type":"exact","sample_size":64,"percentile":43}}},"demographics":{"poster_types":{"member_of_the_public":5,"practitioner":3},"users":{"twitter":{"cohorts":{"Practitioners (doctors, other healthcare professionals)":3,"Members of the public":5}},"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":5,"Librarian":1,"Researcher":29,"Student  > Doctoral Student":8,"Student  > Ph. D. Student":23,"Student  > Postgraduate":9,"Other":20,"Student  > Master":12,"Student  > Bachelor":12,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":6},"by_discipline":{"Medicine and Dentistry":92,"Social Sciences":1,"Physics and Astronomy":1,"Psychology":1,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":15,"Computer Science":1,"Biochemistry, Genetics and Molecular Biology":4,"Mathematics":2,"Unspecified":8,"Pharmacology, Toxicology and Pharmaceutical Science":3}}},"geo":{"twitter":{"BE":1,"GB":2,"ES":1},"mendeley":{"CO":1,"EC":1,"US":4,"JP":1,"DK":1,"BR":4,"FR":1,"ES":2}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/aftimosp\/status\/450299631982096384","license":"public","citation_ids":[2198613],"posted_on":"2014-03-30T15:52:53+00:00","author":{"name":"Philippe Aftimos, MD","url":"http:\/\/be.linkedin.com\/pub\/philippe-aftimos-md\/25\/a76\/664","image":"https:\/\/pbs.twimg.com\/profile_images\/832483544064602112\/cfYg9YGh_normal.jpg","description":"Medical Oncologist and senior research physician at @JulesBordet #Brussels. Developmental therapeutics, #BreastCancer #PrecisionMedicine. Views are my own.","id_on_source":"aftimosp","tweeter_id":"177176270","geo":{"lt":50.85045,"ln":4.34878,"country":"BE"},"followers":2419},"tweet_id":"450299631982096384"},{"url":"http:\/\/twitter.com\/PenrynPam\/status\/450300864381861888","license":"public","rt":["aftimosp"],"citation_ids":[2198613],"posted_on":"2014-03-30T15:57:46+00:00","author":{"name":"Penryn Pam","url":"http:\/\/www.winahomeforlife.co.uk","image":"http:\/\/pbs.twimg.com\/profile_images\/378800000059758588\/318006b9c592aa8c55f6880a711ce896_normal.jpeg","description":"Supporting #BreastCancer - Women need to feel they have a voice when going through Breast Cancer - Page not monitored daily - Enquiries @WinAHome4Life","id_on_source":"PenrynPam","tweeter_id":"1553822702","geo":{"_id":"pam@winnit.co.uk"},"followers":1110},"tweet_id":"450300864381861888"},{"url":"https:\/\/twitter.com\/TripCancer\/status\/496366296729411584","license":"datasift","citation_ids":[2198613],"posted_on":"2014-08-04T18:45:21+00:00","author":{"name":"Trip Cancer","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/429598181408509953\/GGLCJmws_normal.jpeg","description":"All the latest oncology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripCancer","tweeter_id":"2212757204","followers":494},"tweet_id":"496366296729411584"},{"url":"https:\/\/twitter.com\/JRBtrip\/status\/496601542687211520","license":"datasift","rt":["TripCancer"],"citation_ids":[2198613],"posted_on":"2014-08-05T10:20:08+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/848963179799621632\/13FZ5NG4_normal.jpg","description":"Personal account. Also see @tripdatabase and @rapidreviews_i","id_on_source":"JRBtrip","tweeter_id":"14359728","geo":{"lt":51.45523,"ln":-2.59665,"country":"GB"},"followers":2107},"tweet_id":"496601542687211520"},{"url":"https:\/\/twitter.com\/tripdatabase\/status\/501104463965597696","license":"datasift","rt":["TripCancer"],"citation_ids":[2198613],"posted_on":"2014-08-17T20:33:08+00:00","author":{"name":"Trip Database","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/2993778224\/e2ad2bb1255d395571656ead2239a48b_normal.png","description":"Evidence at your fingertips! \nIf you have a clinical Q, Trip can help!  As easy to use as Google, but evidence-based results.","id_on_source":"tripdatabase","tweeter_id":"906554365","geo":{"lt":null,"ln":null},"followers":3091},"tweet_id":"501104463965597696"},{"url":"http:\/\/twitter.com\/Senology\/status\/448103680093724672","license":"public","citation_ids":[2198613],"posted_on":"2014-03-24T14:26:57+00:00","author":{"name":"Senology","url":"http:\/\/www.senology.org","image":"https:\/\/pbs.twimg.com\/profile_images\/1301293396\/logo_style_normal.JPG","description":"Senology.org is the official web site of the International Senologic and Oncologic Scientific Community (ISOSC) - breast diseases and cancer diagnosis and care","id_on_source":"Senology","tweeter_id":"203469783","geo":{"lt":null,"ln":null},"followers":1868},"tweet_id":"448103680093724672"},{"url":"https:\/\/twitter.com\/TripCancer\/status\/501099924805541888","license":"datasift","citation_ids":[2198613],"posted_on":"2014-08-17T20:15:06+00:00","author":{"name":"Trip Cancer","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/429598181408509953\/GGLCJmws_normal.jpeg","description":"All the latest oncology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripCancer","tweeter_id":"2212757204","followers":494},"tweet_id":"501099924805541888"},{"url":"http:\/\/twitter.com\/BibliotecaHUVH\/status\/446581868964880384","license":"public","citation_ids":[2198613],"posted_on":"2014-03-20T09:39:49+00:00","author":{"name":"BibliotecaHUVH. ICS","url":"http:\/\/www.vhebron.net","image":"https:\/\/pbs.twimg.com\/profile_images\/875677660990636032\/7po0FDW5_normal.jpg","description":"Biblioteca Digital de l\u2019Hospital Universitari Vall d\u2019Hebron. Institut Catal\u00e0 de la Salut. Departament de Salut. Generalitat de Catalunya","id_on_source":"BibliotecaHUVH","tweeter_id":"124130301","geo":{"lt":41.38879,"ln":2.15899,"country":"ES"},"followers":2035},"tweet_id":"446581868964880384"},{"url":"http:\/\/twitter.com\/CRWLibrary\/status\/446570431844454400","license":"public","citation_ids":[2198613],"posted_on":"2014-03-20T08:54:22+00:00","author":{"name":"Cancer Library VCC","url":"http:\/\/www.wales.nhs.uk\/velindrelibrary","image":"https:\/\/pbs.twimg.com\/profile_images\/478464349476884480\/YlBsicot_normal.jpeg","description":"The only cancer specialist library service in Wales.  Supporting NHS and academic staff, students and health professionals throughout the Principality.","id_on_source":"CRWLibrary","tweeter_id":"1288296943","geo":{"lt":51.48,"ln":-3.18,"country":"GB"},"followers":650},"tweet_id":"446570431844454400"}],"policy":[{"title":"Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer: Committee papers","url":"https:\/\/www.nice.org.uk\/guidance\/TA424\/documents\/committee-papers-2","license":"public","citation_ids":[2796993,441443,5388592,6003907,15777390,220149,484422,16032151,2432476,20543191,20543196,20543201,20543206,20543213,20543218,20543227,20543230,20543235,20328340,20543244,20543254,20543260,6079779,20543272,3714360,1395822,1965931,20543282,393158,1508999,20543295,6424001,228135,16032153,20543314,16223469,228134,2796993,20543322,17917837,2432348,15418035,4048115,20543341,20543348,20543359,1465466,16676877,1096677,2606863,15063707,662920,3820787,596604,1631861,2198613,482929,3247880,20543422,786661,20543441,6096408,1145378,2604858,4663308,9908035,2120553,3968682,159346,483980,1809776,2873579,17926024,6235475,20543531,4684905,20543554,393158,2796993,4684905,4684905,20543601,4684905],"posted_on":"2016-05-20T00:00:00+00:00","source":{"name":"National Institute for Health and Care Excellence","description":"The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.","geo":{"country":"GB"}},"page_url":"https:\/\/www.nice.org.uk\/guidance\/ta424\/evidence","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-c538532fd05eafb8bcf6a2c191ad82fa133a1b27a3b8c378ef4dfa0be44bcfa4.jpg"}}]}}